NO3221486T3 - - Google Patents
Info
- Publication number
- NO3221486T3 NO3221486T3 NO15775410A NO15775410A NO3221486T3 NO 3221486 T3 NO3221486 T3 NO 3221486T3 NO 15775410 A NO15775410 A NO 15775410A NO 15775410 A NO15775410 A NO 15775410A NO 3221486 T3 NO3221486 T3 NO 3221486T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916827P | 2013-12-17 | 2013-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3221486T3 true NO3221486T3 (fr) | 2018-09-08 |
Family
ID=52355185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO15775410A NO3221486T3 (fr) | 2013-12-17 | 2015-10-02 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9776964B2 (fr) |
| EP (1) | EP3083562B1 (fr) |
| JP (1) | JP6212644B2 (fr) |
| KR (1) | KR101807981B1 (fr) |
| CN (1) | CN105793242B (fr) |
| AU (1) | AU2014366361B2 (fr) |
| BR (1) | BR112016011016A8 (fr) |
| CA (1) | CA2928593A1 (fr) |
| CY (1) | CY1119583T1 (fr) |
| DK (1) | DK3083562T3 (fr) |
| EA (1) | EA028921B1 (fr) |
| ES (1) | ES2651858T3 (fr) |
| HR (1) | HRP20171850T1 (fr) |
| HU (1) | HUE035698T2 (fr) |
| LT (1) | LT3083562T (fr) |
| ME (1) | ME02896B (fr) |
| MX (1) | MX2016007566A (fr) |
| NO (1) | NO3221486T3 (fr) |
| PL (1) | PL3083562T3 (fr) |
| PT (1) | PT3083562T (fr) |
| RS (1) | RS56615B1 (fr) |
| SI (1) | SI3083562T1 (fr) |
| WO (1) | WO2015094902A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| AU2018269666B2 (en) | 2017-05-18 | 2022-02-03 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as PGE2 receptor modulators |
| EP3625224B1 (fr) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | Dérivés d'indole n-substitués |
| CA3063788A1 (fr) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Derives de pyrimidine |
| KR102612649B1 (ko) | 2017-05-18 | 2023-12-11 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 벤조푸란 및 벤조티오페논 유도체 |
| US11839613B2 (en) | 2017-05-18 | 2023-12-12 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| CN109970625B (zh) * | 2017-12-28 | 2021-02-26 | 新发药业有限公司 | 一种5r-苄氧氨基哌啶-2s-甲酸或其衍生物的制备方法 |
| WO2020251957A1 (fr) * | 2019-06-11 | 2020-12-17 | Teon Therapeutics, Inc. | Antagonistes du récepteur 4 de la prostaglandine e2 et leurs utilisations |
| EP3885339A1 (fr) | 2020-03-27 | 2021-09-29 | Rottapharm Biotech S.r.l. | Procédé de préparation de l'acide (r)-4-(1-(6-(4-(trifluorométhyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoïque ou d'un de ses sels |
| KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
| CN112608271A (zh) * | 2020-11-26 | 2021-04-06 | 安润医药科技（苏州）有限公司 | 酰胺衍生物及其在制备ep4受体拮抗剂中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2500157C2 (de) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
| BR0308738A (fr) | 2002-03-18 | 2005-01-11 | ||
| RU2373204C2 (ru) * | 2003-07-28 | 2009-11-20 | Янссен Фармацевтика Н.В. | Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение в качестве модуляторов lta4h |
| EA009201B1 (ru) | 2003-09-03 | 2007-12-28 | Пфайзер Инк. | Фенил - или пиридиламидные соединения в качестве антагонистов простагландина e2 |
| CA2565660C (fr) | 2004-05-04 | 2009-11-03 | Pfizer Inc. | Composes aryl- ou heteroarylamides ortho-substitues |
| CA2565813C (fr) * | 2004-05-04 | 2010-10-26 | Pfizer Inc. | Composes methylaryl- ou heteroarylamides substitues |
| WO2007121578A1 (fr) | 2006-04-24 | 2007-11-01 | Merck Frosst Canada Ltd. | Dérivés d'indolamide comme antagonistes du récepteur ep4 |
| JP5183628B2 (ja) | 2006-06-12 | 2013-04-17 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体 |
| US20110028463A1 (en) * | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| ES2518919T3 (es) | 2008-05-14 | 2014-11-05 | Astellas Pharma Inc. | Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética |
| CA2733247C (fr) | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Derives d'amides heterocycliques en tant qu'antagonistes du recepteur ep4 |
| CA2789665C (fr) | 2010-02-22 | 2020-06-16 | Raqualia Pharma Inc. | Utilisation d'antagonistes de recepteur ep4 dans le traitement de maladies mediees par il-23 |
| WO2013004291A1 (fr) | 2011-07-04 | 2013-01-10 | Rottapharm S.P.A. | Dérivés aminés cycliques en tant qu'agonistes du récepteur ep4 |
| AU2011372747B2 (en) * | 2011-07-04 | 2016-12-22 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor antagonists |
| AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) * | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
-
2014
- 2014-12-11 US US15/030,888 patent/US9776964B2/en not_active Expired - Fee Related
- 2014-12-11 CN CN201480068170.1A patent/CN105793242B/zh not_active Expired - Fee Related
- 2014-12-11 WO PCT/US2014/069743 patent/WO2015094902A1/fr active Application Filing
- 2014-12-11 RS RS20171227A patent/RS56615B1/sr unknown
- 2014-12-11 EA EA201690894A patent/EA028921B1/ru not_active IP Right Cessation
- 2014-12-11 DK DK14827907.8T patent/DK3083562T3/da active
- 2014-12-11 EP EP14827907.8A patent/EP3083562B1/fr active Active
- 2014-12-11 ES ES14827907.8T patent/ES2651858T3/es active Active
- 2014-12-11 LT LTEP14827907.8T patent/LT3083562T/lt unknown
- 2014-12-11 KR KR1020167015741A patent/KR101807981B1/ko active IP Right Grant
- 2014-12-11 MX MX2016007566A patent/MX2016007566A/es unknown
- 2014-12-11 PL PL14827907T patent/PL3083562T3/pl unknown
- 2014-12-11 ME MEP-2017-238A patent/ME02896B/fr unknown
- 2014-12-11 JP JP2016538744A patent/JP6212644B2/ja not_active Expired - Fee Related
- 2014-12-11 PT PT148279078T patent/PT3083562T/pt unknown
- 2014-12-11 AU AU2014366361A patent/AU2014366361B2/en not_active Ceased
- 2014-12-11 HU HUE14827907A patent/HUE035698T2/en unknown
- 2014-12-11 BR BR112016011016A patent/BR112016011016A8/pt not_active IP Right Cessation
- 2014-12-11 CA CA2928593A patent/CA2928593A1/fr not_active Abandoned
- 2014-12-11 SI SI201430434T patent/SI3083562T1/sl unknown
-
2015
- 2015-10-02 NO NO15775410A patent/NO3221486T3/no unknown
-
2017
- 2017-11-09 CY CY20171101176T patent/CY1119583T1/el unknown
- 2017-11-28 HR HRP20171850TT patent/HRP20171850T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014366361B2 (en) | 2017-04-20 |
| LT3083562T (lt) | 2018-01-10 |
| CN105793242A (zh) | 2016-07-20 |
| EP3083562A1 (fr) | 2016-10-26 |
| HRP20171850T1 (hr) | 2018-01-12 |
| RS56615B1 (sr) | 2018-02-28 |
| EA201690894A1 (ru) | 2016-10-31 |
| EA028921B1 (ru) | 2018-01-31 |
| BR112016011016A8 (pt) | 2018-01-30 |
| CY1119583T1 (el) | 2018-03-07 |
| ME02896B (fr) | 2018-04-20 |
| PT3083562T (pt) | 2017-12-13 |
| DK3083562T3 (da) | 2017-11-13 |
| KR101807981B1 (ko) | 2017-12-11 |
| JP2016540007A (ja) | 2016-12-22 |
| MX2016007566A (es) | 2016-10-03 |
| AU2014366361A1 (en) | 2016-05-19 |
| JP6212644B2 (ja) | 2017-10-11 |
| WO2015094902A1 (fr) | 2015-06-25 |
| SI3083562T1 (sl) | 2017-11-30 |
| CA2928593A1 (fr) | 2015-06-25 |
| HUE035698T2 (en) | 2018-05-28 |
| KR20160084467A (ko) | 2016-07-13 |
| PL3083562T3 (pl) | 2018-02-28 |
| EP3083562B1 (fr) | 2017-09-27 |
| ES2651858T3 (es) | 2018-01-30 |
| US9776964B2 (en) | 2017-10-03 |
| US20160272585A1 (en) | 2016-09-22 |
| CN105793242B (zh) | 2018-02-16 |